ArticleVeterinary world2020
Monitoring of serum and urinary biomarkers during treatment of canine visceral leishmaniasis.
Article in Veterinary world, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
- Urinary neutrophil gelatinase-associated lipocalin in dogs: accuracy of a novel rapid test and biomarker behavior across clinical settings.Journal of veterinary internal medicine · 2026Article
- Urinary Gamma-Glutamil Transferase as an Early Biomarker of Renal Disease in Dogs with Leishmaniosis.Veterinary sciences · 2025Article
- Treatment ofMicroorganisms · 2025Review
- Relationship between urinary neutrophil gelatinase-associated lipocalin and selected biochemical and urinary parameters in dogs naturally infected withVeterinary world · 2024Article
- Short Term Treatment Monitoring of Renal and Inflammatory Biomarkers with Naturally Occurring Leishmaniosis: A Cohort Study of 30 Dogs.Veterinary sciences · 2024Article
- Distribution of and Relationships between Epidemiological and Clinicopathological Parameters in Canine Leishmaniosis: A Retrospective Study of 15 Years (2009-2023).Pathogens (Basel, Switzerland) · 2024Article
- Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol.Tropical medicine and infectious disease · 2023Article
- Retrospective Long-Term Evaluation of Miltefosine-Allopurinol Treatment in Canine Leishmaniosis.Pathogens (Basel, Switzerland) · 2023Article
- Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention.Veterinary sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCanine visceral leishmaniasis (CanL) has a broad spectrum of changes, with kidney disease being considered the main cause of mortality. Thus, this study aimed to monitor serum and urinary biomarkers in response to two short-term treatments for CanL. MATERIALS AND
methodsThirty dogs with CanL were equally divided into two treatment groups and treated with either miltefosine (Group M) or miltefosine plus allopurinol (Group MA); the groups were evaluated before treatment and after 28 days of treatment. Physical exams were performed and hematimetric, biochemical, and urinary parameters, including urinary biomarkers cystatin C (CisC), lipocalin-2 (NGAL), and microalbuminuria, were measured.
resultsBoth treatments significantly reduced clinical scores (p<0.05), but only the MA group saw a reduction in the clinical-pathological score. The serum albumin and calcium levels increased significantly in the MA and M groups (p<0.05). Proteinuria and urinary density did not decrease significantly after the treatments. With regard to the biomarkers, CisC and microalbuminuria did not have any significant changes; however, NGAL was significantly reduced in the MA group (p<0.05).
conclusionBoth pharmacotherapeutic protocols promoted clinical and clinical-pathological improvements. In addition, miltefosine plus allopurinol proved to be a safe treatment due to the lack of changes detected in the monitored renal biomarkers. The treatment with miltefosine plus allopurinol proved to be the most effective, with more pronounced beneficial effects for canines with visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.